Sun W, Zhou Y, Lin Y, Feng S, Long H
Zhongguo Fei Ai Za Zhi. 2025; 27(11):849-854.
PMID: 39800480
PMC: 11732383.
DOI: 10.3779/j.issn.1009-3419.2024.106.30.
Kemper M, Elges S, Kies P, Wiebe K, Lenz G, Bleckmann A
Transl Lung Cancer Res. 2024; 13(10):2813-2827.
PMID: 39507015
PMC: 11535839.
DOI: 10.21037/tlcr-24-359.
Zheng Y, Zhao F, Ren Y, Xue Y, Yan B, Huang C
Front Pharmacol. 2024; 15:1401428.
PMID: 39144623
PMC: 11321957.
DOI: 10.3389/fphar.2024.1401428.
Cortinovis D, Leonetti A, Morabito A, Sala L, Tiseo M
Cancers (Basel). 2024; 16(14).
PMID: 39061248
PMC: 11275113.
DOI: 10.3390/cancers16142610.
Seong H, Kim S, Kim M, Cho J, Kim A, Eom J
Front Oncol. 2024; 14:1343238.
PMID: 39055554
PMC: 11269150.
DOI: 10.3389/fonc.2024.1343238.
Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report.
Li J, Liu J, Zhang G, Hu W, Wang X, Liu J
Am J Case Rep. 2023; 24:e942150.
PMID: 37934724
PMC: 10642716.
DOI: 10.12659/AJCR.942150.
Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy.
Cao P, Zhao Q, Li Y, Shi R, Zhu G, Zhang Z
Front Pharmacol. 2023; 14:1140894.
PMID: 37663243
PMC: 10470069.
DOI: 10.3389/fphar.2023.1140894.
Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report.
Wang L, Zhao P, Sun X, Yan F, Guo Q
World J Clin Cases. 2023; 11(22):5322-5328.
PMID: 37621597
PMC: 10445061.
DOI: 10.12998/wjcc.v11.i22.5322.
Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports.
Shi L, Gao S, Tong L, Meng Q, Zhou S, Yu D
Front Oncol. 2023; 13:1120511.
PMID: 37409244
PMC: 10318538.
DOI: 10.3389/fonc.2023.1120511.
Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer.
Zheng N, Zhang Y, Zeng Y, Ma Q, Zhang R, Zhao Q
Target Oncol. 2023; 18(4):625-636.
PMID: 37351800
DOI: 10.1007/s11523-023-00981-7.
Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib.
Zhai X, Wang T, Lin Y, Zhang J, Wang Y, Wang W
Front Oncol. 2023; 13:1104910.
PMID: 37064118
PMC: 10095823.
DOI: 10.3389/fonc.2023.1104910.
Early-stage anaplastic lymphoma kinase ()-positive lung cancer: a narrative review.
Chen M, Chaft J
Transl Lung Cancer Res. 2023; 12(2):337-345.
PMID: 36895922
PMC: 9989809.
DOI: 10.21037/tlcr-22-631.
Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer.
Hu Y, Ren S, Wang R, Han W, Xiao P, Wang L
Front Pharmacol. 2022; 13:816683.
PMID: 35873553
PMC: 9299059.
DOI: 10.3389/fphar.2022.816683.
Neoadjuvant ceritinib treatment in ALK-rearranged locally advanced adenosquamous carcinoma: A case report.
Mai S, Wang Y, Wang X, Yang W, Gao H, Xu Z
Thorac Cancer. 2022; 13(15):2275-2278.
PMID: 35818908
PMC: 9346166.
DOI: 10.1111/1759-7714.14558.
Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement.
Zhou N, Li T, Liang M, Ren F, Ni H, Liu W
Front Oncol. 2022; 12:848779.
PMID: 35223529
PMC: 8866561.
DOI: 10.3389/fonc.2022.848779.
Perioperative alectinib in a patient with locally advanced anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC): a case report.
Yue P, Zhang S, Zhou L, Xiang J, Zhao S, Chen X
Transl Cancer Res. 2022; 10(8):3856-3863.
PMID: 35116684
PMC: 8799071.
DOI: 10.21037/tcr-21-642.
Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review.
Gu R, Shi Z, Duan T, Song M
Onco Targets Ther. 2021; 14:5107-5113.
PMID: 34707369
PMC: 8544264.
DOI: 10.2147/OTT.S334213.
Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report.
Zhao S, Zhu S, Lei X, Xu D, Shi T, Chen Q
Thorac Cancer. 2021; 12(20):2815-2818.
PMID: 34405544
PMC: 8520795.
DOI: 10.1111/1759-7714.14112.
